Trust Company of Vermont’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.56M Buy
+12,339
New +$1.63M 0.06% 183
2025
Q4
$1.47M Sell
11,985
-115
-1% -$14K 0.06% 170
2025
Q3
$1.34M Buy
12,100
+124
+1% +$14.1K 0.06% 175
2025
Q2
$1.33M Buy
11,976
+320
+3% +$34.1K 0.06% 169
2025
Q1
$1.31M Sell
11,656
-70
-0.6% -$7.22K 0.07% 169
2024
Q4
$1.08M Buy
11,726
+2,176
+23% +$196K 0.05% 179
2024
Q3
$801K Sell
9,550
-423
-4% -$32.3K 0.04% 193
2024
Q2
$684K Buy
9,973
+31
+0.3% +$2.07K 0.04% 203
2024
Q1
$728K Buy
9,942
+456
+5% +$35.1K 0.04% 199
2023
Q4
$768K Buy
9,486
+1,220
+15% +$94.9K 0.05% 182
2023
Q3
$619K Buy
8,266
+1,139
+16% +$87.6K 0.04% 197
2023
Q2
$549K Buy
7,127
+2,500
+54% +$199K 0.04% 214
2023
Q1
$384K Sell
4,627
-34
-0.7% -$2.82K 0.03% 248
2022
Q4
$400K Sell
4,661
-1,281
-22% -$101K 0.03% 238
2022
Q3
$366K Buy
5,942
+1,272
+27% +$80.2K 0.03% 235
2022
Q2
$288K Sell
4,670
-341
-7% -$21.1K 0.02% 260
2022
Q1
$297K Buy
5,011
+60
+1% +$3.83K 0.02% 268
2021
Q4
$359K Sell
4,951
-1,193
-19% -$82.2K 0.02% 259
2021
Q3
$430K Sell
6,144
-240
-4% -$16.9K 0.03% 230
2021
Q2
$439K Sell
6,384
-2,146
-25% -$143K 0.03% 232
2021
Q1
$551K Sell
8,530
-1,662
-16% -$107K 0.04% 212
2020
Q4
$594K Sell
10,192
-1,456
-13% -$87.9K 0.05% 190
2020
Q3
$736K Sell
11,648
-500
-4% -$34.7K 0.07% 170
2020
Q2
$934K Sell
12,148
-4,343
-26% -$333K 0.09% 156
2020
Q1
$1.23M Sell
16,491
-6,060
-27% -$419K 0.12% 141
2019
Q4
$1.47M Sell
22,551
-8,772
-28% -$571K 0.11% 147
2019
Q3
$1.99M Sell
31,323
-3,369
-10% -$220K 0.16% 121
2019
Q2
$2.34M Sell
34,692
-2,048
-6% -$135K 0.19% 105
2019
Q1
$2.39M Sell
36,740
-2,583
-7% -$172K 0.21% 104
2018
Q4
$2.46M Sell
39,323
-4,906
-11% -$343K 0.24% 98
2018
Q3
$3.42M Buy
44,229
+1,161
+3% +$87.7K 0.29% 90
2018
Q2
$3.05M Buy
43,068
+1,158
+3% +$81.8K 0.27% 95
2018
Q1
$3.16M Buy
41,910
+267
+0.6% +$21.2K 0.3% 93
2017
Q4
$2.98M Buy
41,643
+54
+0.1% +$4.1K 0.28% 99
2017
Q3
$3.37M Buy
41,589
+10
+0% +$765 0.34% 90
2017
Q2
$2.94M Sell
41,579
-2,446
-6% -$163K 0.3% 93
2017
Q1
$2.99M Buy
44,025
+1,644
+4% +$116K 0.32% 91
2016
Q4
$3.04M Sell
42,381
-9,731
-19% -$723K 0.35% 82
2016
Q3
$4.12M Buy
52,112
+3,201
+7% +$260K 0.52% 66
2016
Q2
$4.08M Sell
48,911
-2,482
-5% -$220K 0.54% 64
2016
Q1
$4.72M Buy
51,393
+2,106
+4% +$190K 0.66% 52
2015
Q4
$4.99M Buy
49,287
+4,293
+10% +$447K 0.71% 47
2015
Q3
$4.42M Buy
44,994
+8,828
+24% +$980K 0.69% 47
2015
Q2
$4.23M Buy
36,166
+3,608
+11% +$394K 0.62% 51
2015
Q1
$3.19M Buy
32,558
+5,738
+21% +$583K 0.46% 67
2014
Q4
$2.53M Buy
26,820
+517
+2% +$53.5K 0.37% 85
2014
Q3
$2.8M Buy
26,303
+304
+1% +$29.8K 0.42% 74
2014
Q2
$2.15M Buy
25,999
+3,081
+13% +$240K 0.33% 88
2014
Q1
$1.62M Buy
22,918
+3,823
+20% +$300K 0.27% 104
2013
Q4
$1.43M Buy
19,095
+5,644
+42% +$393K 0.24% 107
2013
Q3
$845K Buy
13,451
+3,005
+29% +$180K 0.16% 133
2013
Q2
$536K Buy
+10,446
New +$544K 0.1% 148

Other funds holding GILD

Trust Company of Vermont's GILD Position: Q2 2026 in Review

Trust Company of Vermont opened a new position in Gilead Sciences (GILD) in Q2 2026: 12,339 shares worth $1.56M. The stake represents 0.06% of the portfolio and ranks #183 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in GILD as recently as Q4 2025.

Trust Company of Vermont first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.99M in Q4 2015. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Trust Company of Vermont held 12,339 shares of Gilead Sciences worth $1.56M as of Q2 2026.
  • Gilead Sciences was a new Trust Company of Vermont position in Q2 2026.
  • Gilead Sciences made up 0.06% of Trust Company of Vermont's portfolio in Q2 2026, its #183 holding.
  • Trust Company of Vermont first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Trust Company of Vermont's Gilead Sciences position peaked at $4.99M in Q4 2015.
  • 1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.